Consolidated segment reporting
All figures are reported excluding the discontinued operations of Fresenius Vamed, except for net income.
|
|
Fresenius Kabi |
|
Fresenius Helios |
|
Corporate/Other |
|
Fresenius Group |
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
€ in millions |
|
20251 |
|
20241 |
|
Growth |
|
20251 |
|
20241 |
|
Growth |
|
20252 |
|
|
Growth |
|
2025 |
|
20243 |
|
Growth |
|||||||||||||||
Revenue |
|
8,612 |
|
8,414 |
|
2% |
|
13,550 |
|
12,739 |
|
6% |
|
711 |
|
801 |
|
-11% |
|
22,873 |
|
21,954 |
|
4% |
||||||||||||||
thereof contribution |
|
8,559 |
|
8,362 |
|
2% |
|
13,543 |
|
12,730 |
|
6% |
|
771 |
|
862 |
|
-11% |
|
22,873 |
|
21,954 |
|
4% |
||||||||||||||
thereof intercompany revenue |
|
53 |
|
52 |
|
2% |
|
7 |
|
9 |
|
-22% |
|
-60 |
|
-61 |
|
2% |
|
– |
|
– |
|
|
||||||||||||||
contribution to consolidated revenue |
|
37% |
|
38% |
|
|
|
59% |
|
58% |
|
|
|
4% |
|
4% |
|
|
|
100% |
|
100% |
|
|
||||||||||||||
Costs of revenue |
|
-4,861 |
|
-4,798 |
|
-1% |
|
-11,553 |
|
-10,760 |
|
-7% |
|
-766 |
|
-759 |
|
-1% |
|
-17,180 |
|
-16,317 |
|
-5% |
||||||||||||||
EBITDA |
|
1,934 |
|
1,875 |
|
3% |
|
1,863 |
|
1,805 |
|
3% |
|
-367 |
|
-367 |
|
0% |
|
3,430 |
|
3,313 |
|
4% |
||||||||||||||
Depreciation and amortization |
|
521 |
|
556 |
|
-6% |
|
535 |
|
517 |
|
3% |
|
64 |
|
167 |
|
-62% |
|
1,120 |
|
1,240 |
|
-10% |
||||||||||||||
EBIT |
|
1,413 |
|
1,319 |
|
7% |
|
1,328 |
|
1,288 |
|
3% |
|
-431 |
|
-534 |
|
19% |
|
2,310 |
|
2,073 |
|
11% |
||||||||||||||
Net interest / other financial result |
|
-101 |
|
-130 |
|
22% |
|
-207 |
|
-270 |
|
23% |
|
-12 |
|
-29 |
|
59% |
|
-320 |
|
-429 |
|
25% |
||||||||||||||
Income taxes |
|
-294 |
|
-284 |
|
-4% |
|
-263 |
|
-236 |
|
-11% |
|
-25 |
|
-10 |
|
-150% |
|
-582 |
|
-530 |
|
-10% |
||||||||||||||
Noncontrolling interests |
|
59 |
|
52 |
|
13% |
|
10 |
|
10 |
|
0% |
|
1 |
|
-38 |
|
103% |
|
70 |
|
24 |
|
192% |
||||||||||||||
Income from investments accounted for using the equity method |
|
n.a. |
|
n.a. |
|
|
|
n.a. |
|
n.a. |
|
|
|
198 |
|
38 |
|
-- |
|
198 |
|
38 |
|
-- |
||||||||||||||
Net income from discontinued Fresenius Vamed operations |
|
n.a. |
|
n.a. |
|
|
|
n.a. |
|
n.a. |
|
|
|
-272 |
|
-657 |
|
59% |
|
-272 |
|
-657 |
|
59% |
||||||||||||||
Net income attributable to shareholders |
|
959 |
|
853 |
|
12% |
|
848 |
|
772 |
|
10% |
|
-543 |
|
-1,154 |
|
53% |
|
1,264 |
|
471 |
|
168% |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Operating cash flow |
|
1,279 |
|
1,178 |
|
9% |
|
1,607 |
|
1,575 |
|
2% |
|
-312 |
|
-306 |
|
-2% |
|
2,574 |
|
2,447 |
|
5% |
||||||||||||||
Cash flow before acquisitions and dividends |
|
914 |
|
798 |
|
15% |
|
1,070 |
|
1,061 |
|
1% |
|
-102 |
|
-236 |
|
57% |
|
1,882 |
|
1,623 |
|
16% |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Assets excl. Fresenius Medical Care |
|
15,579 |
|
16,594 |
|
-6% |
|
23,405 |
|
22,192 |
|
5% |
|
-401 |
|
1,125 |
|
-136% |
|
38,583 |
|
39,911 |
|
-3% |
||||||||||||||
Fresenius Medical Care investment |
|
n.a. |
|
n.a. |
|
|
|
n.a. |
|
n.a. |
|
|
|
2,813 |
|
3,639 |
|
-23% |
|
2,813 |
|
3,639 |
|
-23% |
||||||||||||||
Debt |
|
2,768 |
|
3,568 |
|
-22% |
|
7,244 |
|
7,269 |
|
0% |
|
1,921 |
|
2,740 |
|
-30% |
|
11,933 |
|
13,577 |
|
-12% |
||||||||||||||
Other operating liabilities |
|
3,898 |
|
4,004 |
|
-3% |
|
3,945 |
|
3,573 |
|
10% |
|
1,244 |
|
1,479 |
|
-16% |
|
9,087 |
|
9,056 |
|
0% |
||||||||||||||
Capital expenditure, gross |
|
382 |
|
395 |
|
-3% |
|
537 |
|
517 |
|
4% |
|
82 |
|
48 |
|
71% |
|
1,001 |
|
960 |
|
4% |
||||||||||||||
Acquisitions, gross / investments |
|
31 |
|
50 |
|
-38% |
|
60 |
|
7 |
|
-- |
|
301 |
|
18 |
|
-- |
|
392 |
|
75 |
|
-- |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Research and development expenses |
|
621 |
|
631 |
|
-2% |
|
1 |
|
3 |
|
-67% |
|
11 |
|
7 |
|
57% |
|
633 |
|
641 |
|
-1% |
||||||||||||||
Employees (per capita |
|
40,913 |
|
41,586 |
|
-2% |
|
130,240 |
|
128,558 |
|
1% |
|
7,241 |
|
6,342 |
|
14% |
|
178,394 |
|
176,486 |
|
1% |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Key figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
EBITDA margin |
|
22.5% |
|
22.3% |
|
|
|
13.7% |
|
14.2% |
|
|
|
|
|
|
|
|
|
16.4%1 |
|
16.8%1 |
|
|
||||||||||||||
EBIT margin |
|
16.4% |
|
15.7% |
|
|
|
9.8% |
|
10.1% |
|
|
|
|
|
|
|
|
|
11.5%1 |
|
11.6%1 |
|
|
||||||||||||||
Depreciation and amortization |
|
6.0% |
|
6.6% |
|
|
|
3.9% |
|
4.1% |
|
|
|
|
|
|
|
|
|
4.9%1 |
|
5.2%1 |
|
|
||||||||||||||
Operating cash flow in % of revenue |
|
14.9% |
|
14.0% |
|
|
|
11.9% |
|
12.4% |
|
|
|
|
|
|
|
|
|
11.4%1 |
|
11.4%1 |
|
|
||||||||||||||
ROIC |
|
8.8% |
|
8.0% |
|
|
|
6.1% |
|
5.8% |
|
|
|
|
|
|
|
|
|
6.6%4 |
|
6.2%4 |
|
|
||||||||||||||
|
||||||||||||||||||||||||||||||||||||||